NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE235765 Query DataSets for GSE235765
Status Public on Feb 12, 2024
Title Expression data from healthy C57BL/6 mice treated with BAMLET
Organism Mus musculus
Experiment type Expression profiling by array
Summary Tumor surveillance is essential to stop tumor progenitors in their tracks. Clearly, endogenous protective mechanisms other than immune surveillance are important, but their molecular nature and mechanisms of action remain unclear. In the newborn intestine, the immature cells need to be surveilled to promote differentiation and tumor development prevented. This study addressed if molecules in milk may be relevant for tumor surveillance. Alpha-lactalbumin, which is the most abundant protein in human milk and crucial for the survival of mammals, due to its role in lactose synthesis, also forms tumoricidal oleic-acid complexes with documented therapeutic efficacy. This study identifies BAMLET, a complex formed by bovine alpha-lactalbumin and oleic acid, as a tumor surveillance molecule. BAMLET substitution of the drinking water protected tumor-prone ApcMin/+ mice from developing intestinal cancer and prolonged their survival, with pronounced inhibition of genes regulating the tumor environment, metastasis, Wnt/β-catenin signaling and cancer related gene networks. Unexpected extra-intestinal effects on lungs, livers, kidneys and spleens further suggested a protective effect of BAMLET beyond the intestine. These effects were specific for the cancer-prone ApcMin/+ mice. Healthy C57BL/6 mice were largely unaffected by peroral BAMLET administration, except for improved metabolic functions such as lipid and glucose metabolism and insulin resistance and there was no evidence of toxicity. The results suggest that molecules, which have evolved to support tissue differentiation, may identify and remove tumor progenitors. The findings support the potential of BAMLET as a tumor surveillance molecule with potential for clinical use in cancer-prone patients.
 
Overall design Female C57BL/6 mice received 20 mg of BAMLET in 2 x 200 μl PBS (BAMLET) or 2 x 200 μl of PBS alone (sham) by daily gavage for ten days. The mice were sacrificed two or five weeks after the end of treatment. Alternatively, mice received 20 mg of BAMLET in 5 ml PBS or PBS alone, daily in the drinking water until sacrifice after eight weeks. RNA isolated from intestine was subjected to Affymetrix whole genome transcriptomic analysis.
 
Contributor(s) Tran H, Wan M, Ambite I, Svanborg C
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Jun 26, 2023
Last update date Feb 13, 2024
Contact name Ines Ambite
E-mail(s) [email protected]
Organization name Lund University
Department Laboratory Medicine
Lab MIG
Street address Klinikgatan 28
City Lund
ZIP/Postal code 22184
Country Sweden
 
Platforms (1)
GPL11180 [HT_MG-430_PM] Affymetrix HT MG-430 PM Array Plate
Samples (8)
GSM7508986 bl6_intestine_S1_exp1 [HT_MG-430_PM]
GSM7508987 bl6_intestine_S2_exp1 [HT_MG-430_PM]
GSM7508988 bl6_intestine_S3_exp1 [HT_MG-430_PM]
This SubSeries is part of SuperSeries:
GSE235767 Colon cancer treatment with BAMLET
Relations
BioProject PRJNA987588

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE235765_RAW.tar 16.3 Mb (http)(custom) TAR (of CEL)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap